diazooxonorleucine and Neoplasms

diazooxonorleucine has been researched along with Neoplasms in 24 studies

Research

Studies (24)

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (54.17)	18.7374
1990's	1 (4.17)	18.2507
2000's	1 (4.17)	29.6817
2010's	3 (12.50)	24.3611
2020's	6 (25.00)	2.80

Authors

Authors	Studies
Estok, TM; Wild, R; Yokoyama, Y	1
Hoque, M; Khan, AU; Khan, MI; Suhail, M; Tabrez, S; Zughaibi, TA	1
Aguilar, JMH; Alt, J; Arwood, ML; Dash, RP; Lam, J; Lemberg, KM; Leone, RD; Majer, P; Pal, A; Pandey, R; Peters, DE; Powell, JD; Rais, R; Seiwert, T; Slusher, BS; Tallon, C; Tenora, L; Thomas, AG; Wu, Y; Zhao, L	1
Bader, JE; Chi, C; Fisher, EL; Hathaway, ES; Karijolich, J; Landis, MD; Madden, MZ; Muka, JE; Needle, GA; O'Neil, RT; Patterson, AR; Philip, M; Rathmell, JC; Reinfeld, BI; Wolf, MM; Ye, X	1
Alt, J; Gori, S; Lam, J; Majer, P; Mettu, VS; Novotná, K; Paule, J; Prchalová, E; Rais, R; Slusher, BS; Šnajdr, I; Tenora, L; Tsukamoto, T; Veeravalli, V; Wu, Y	1
Sun, L; Xin, Y; Yang, X; Yu, W; Yuan, S; Zhang, Q	1
Lemberg, KM; Rais, R; Slusher, BS; Vornov, JJ	1
COFFEY, GL; EHRLICH, J; FISHER, MW; HILLEGAS, AB; KOHBERGER, DL; MACHAMER, HE; RIGHTSEL, WA; ROEGNER, FR	1
MAXWELL, RE; NICKEL, VS	1
Cervantes-Madrid, D; Dueñas-González, A	1
Cervantes-Madrid, D; Dueñas-González, A; Romero, Y	1
MAGILL, GB; MYERS, WP	1
JACQUEZ, JA	2
HUTCHISON, DJ; JACQUEZ, JA	1
BAKER, BR	1
Banerjee, M; Ghosh, S; Maity, P; Roy, S	1
Davis, HL; Earhart, RH; Koeller, JM	1
Casper, ES; Magill, GB; Sklaroff, RB; Young, CW	1
Souba, WW	1
Catane, R; Glaubiger, DL; Muggia, FM; Von Hoff, DD	1
Burchenal, JH	1
Feldman, S; Nelson, JA; Sullivan, MP; Van Nguyen, B	1
Carter, SK; Cooney, DA; Livingston, RB; Venditti, JM	1

Reviews

6 review(s) available for diazooxonorleucine and Neoplasms

Article	Year
Targeting GLS1 to cancer therapy through glutamine metabolism. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:11 Topics: Apoptosis; Benzophenanthridines; Cell Proliferation; Diazooxonorleucine; Disease Progression; Drug Resistance, Neoplasm; Genes, myc; Glutaminase; Glutamine; Humans; MicroRNAs; Neoplasm Proteins; Neoplasms; NF-kappa B; Oxidation-Reduction; Phosphates; Prognosis; Retinoblastoma Protein; Sulfides; Thiadiazoles	2021
We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of Molecular cancer therapeutics, 2018, Volume: 17, Issue:9 Topics: Animals; Antimetabolites, Antineoplastic; Diazooxonorleucine; Glutamine; Humans; Molecular Structure; Nausea; Neoplasms; Prodrugs; Vomiting	2018
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy. BioMed research international, 2015, Volume: 2015 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Diazooxonorleucine; Humans; Indazoles; Neoplasms	2015
Glutamine and cancer. Annals of surgery, 1993, Volume: 218, Issue:6 Topics: Antimetabolites, Antineoplastic; Cell Division; Diazooxonorleucine; Glutamine; Humans; Intestinal Mucosa; Intestines; Isoxazoles; Lymphocytes; Muscles; Neoplasms; Parenteral Nutrition, Total; Randomized Controlled Trials as Topic	1993
Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer treatment reports, 1979, Volume: 63, Issue:6 Topics: Animals; Antineoplastic Agents; Azaserine; Azo Compounds; Colonic Neoplasms; Diazooxonorleucine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Transplantation, Heterologous	1979
Glutamine antagonists in chemotherapy. Advances in pharmacology and chemotherapy, 1970, Volume: 8 Topics: Adult; Aminobutyrates; Animals; Asparaginase; Azaserine; Azo Compounds; Child; Diazooxonorleucine; Drug Combinations; Drug Interactions; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; Hydroxylysine; Leukemia; Leukemia L1210; Liver; Methionine Sulfoximine; Mice; Neoplasms; Rats; RNA, Transfer	1970

Other Studies

18 other study(ies) available for diazooxonorleucine and Neoplasms

Article	Year
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems. Molecular cancer therapeutics, 2022, 10-07, Volume: 21, Issue:10 Topics: Amino Acids, Essential; Cell Line, Tumor; Diazooxonorleucine; Glutamine; Humans; Immune System; Neoplasms; Prodrugs; Tumor Microenvironment	2022
Targeting Glutaminase by Natural Compounds: Structure-Based Virtual Screening and Molecular Dynamics Simulation Approach to Suppress Cancer Progression. Molecules (Basel, Switzerland), 2022, 08-08, Volume: 27, Issue:15 Topics: Diazooxonorleucine; Early Detection of Cancer; Glutaminase; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Neoplastic Processes	2022
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Science advances, 2022, 11-18, Volume: 8, Issue:46 Topics: CD8-Positive T-Lymphocytes; Diazooxonorleucine; Enzyme Inhibitors; Glutamine; Humans; Neoplasms; Prodrugs	2022
Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells. Journal of immunology (Baltimore, Md. : 1950), 2023, 08-15, Volume: 211, Issue:4 Topics: Animals; CD8-Positive T-Lymphocytes; Diazooxonorleucine; Glutamine; Mice; Neoplasms	2023
Discovery of Journal of medicinal chemistry, 2023, Nov-23, Volume: 66, Issue:22 Topics: Diazooxonorleucine; Esters; Glutamine; Humans; Neoplasms; Prodrugs	2023
6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies. Antibiotics & chemotherapy (Northfield, Ill.), 1956, Volume: 6, Issue:8 Topics: Bacteria; Biological Products; Diazooxonorleucine; Fungi; Humans; Leucine; Neoplasms	1956
6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. V. Microbiologic studies of mode of action. Antibiotics & chemotherapy (Northfield, Ill.), 1957, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Diazooxonorleucine; Escherichia coli; Leucine; Neoplasms	1957
Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. Oncology reports, 2015, Volume: 34, Issue:3 Topics: Animals; Apoptosis; Cell Survival; Diazooxonorleucine; Drug Synergism; Fatty Acid Synthases; Fatty Acids; Fibroblasts; Gene Expression Regulation, Neoplastic; Glutaminase; Glycolysis; Hexokinase; Humans; Indazoles; Lactones; Metabolic Networks and Pathways; Mice; Neoplasms; Orlistat	2015
Alterations in calcium metabolism in cancer patients treated with 6-diazo-5-oxo-L-norleucine. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1956, Volume: 93, Issue:2 Topics: Calcium; Diazooxonorleucine; Leucine; Neoplasms; Water-Electrolyte Balance	1956
Active transport of O-diazoacetyl-L-serine and 6-diazo-5-oxo-L-norleucine in Ehrlich ascites carcinoma. Cancer research, 1957, Volume: 17, Issue:9 Topics: Antineoplastic Agents; Ascites; Azaserine; Biological Transport, Active; Carcinoma; Diazooxonorleucine; Leucine; Neoplasms; Serine	1957
Concentrative uptake of 6-diazo-5-oxo-L-norleucine by sarcoma 180, liver and muscle in vivo. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1958, Volume: 99, Issue:3 Topics: Animals; Antineoplastic Agents; Diazooxonorleucine; Encephalomyelitis; Leucine; Liver; Muscles; Neoplasms; Sarcoma 180	1958
Resistance in L1210 ascites without change in concentrative uptake of o-diazoacetyl-L-serine or 6-diazo-5-oxo-L-norleucine. Cancer research, 1959, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Ascites; Azaserine; Diazooxonorleucine; Leucine; Neoplasms; Serine	1959
Potential anti-cancer agents--II. A proposed mechanism for the anti-cancer action of L-azaserine and 6-diazo-5-oxo-L-norleucine. Biochemical pharmacology, 1959, Volume: 2 Topics: Antineoplastic Agents; Azaserine; Diazooxonorleucine; Leucine; Neoplasms; Serine	1959
Modulation of tumor induced angiogenesis in Ehrlich ascites tumor. Journal of experimental & clinical cancer research : CR, 2004, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Proliferation; Diazooxonorleucine; Dose-Response Relationship, Drug; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Time Factors; Vascular Endothelial Growth Factor A	2004
Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer treatment reports, 1982, Volume: 66, Issue:5 Topics: Azo Compounds; Diazooxonorleucine; Drug Administration Schedule; Drug Evaluation; Humans; Neoplasms	1982
Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer treatment reports, 1980, Volume: 64, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azo Compounds; Bone Marrow; Carcinoma, Squamous Cell; Diazooxonorleucine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Vomiting	1980
Antitumor effects of azaserine and DON. Cancer treatment reports, 1979, Volume: 63, Issue:6 Topics: Animals; Antineoplastic Agents; Azaserine; Azo Compounds; Diazooxonorleucine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Experimental; Mice; Neoplasms	1979
Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:1 Topics: Adolescent; Azo Compounds; Child; Child, Preschool; Diazooxonorleucine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Injections, Intravenous; Male; Neoplasms	1988